Vermillion (VRML) Shares on the Move as Co. Gets Patent for Platelet Biomarkers for Cancer
Tweet Send to a FriendGet Alerts VRML Hot Sheet
Up)
Trade VRML Now!
Shares of Vermillion (Nasdaq: VRML) have just surged in mid-day trade Tuesday as Bloomberg is reporting the company has received a patent for its platelet biomarkers for cancer.
The stock last traded at $2.10, up more than 12 percent for the session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The stock last traded at $2.10, up more than 12 percent for the session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Liberty Global (LBTYA) Interested in Kabel Deutschland - FT
- UPDATE: Herbalife (HLF) Sees Intra-Day Pressure
- Petrobras (PBR), SINOPEC (SNP) Enter Joint Development Agreement for Maranhão Refinery
Create E-mail Alert Related Categories
Corporate News, Rumors
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
